Cargando…

Coagulopathy in newborns with hypoxic ischemic encephalopathy (HIE) treated with therapeutic hypothermia: a retrospective case-control study

BACKGROUND: Newborns with hypoxic ischemic encephalopathy (HIE) are at risk for coagulopathy due to systemic oxygen deprivation. Additionally, therapeutic hypothermia (TH) slows enzymatic activity of the coagulation cascade, leading to constitutive prolongation of routinely assessed coagulation stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Forman, Katie R, Diab, Yaser, Wong, Edward CC, Baumgart, Stephen, Luban, Naomi LC, Massaro, An N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289197/
https://www.ncbi.nlm.nih.gov/pubmed/25367591
http://dx.doi.org/10.1186/1471-2431-14-277
_version_ 1782352063673401344
author Forman, Katie R
Diab, Yaser
Wong, Edward CC
Baumgart, Stephen
Luban, Naomi LC
Massaro, An N
author_facet Forman, Katie R
Diab, Yaser
Wong, Edward CC
Baumgart, Stephen
Luban, Naomi LC
Massaro, An N
author_sort Forman, Katie R
collection PubMed
description BACKGROUND: Newborns with hypoxic ischemic encephalopathy (HIE) are at risk for coagulopathy due to systemic oxygen deprivation. Additionally, therapeutic hypothermia (TH) slows enzymatic activity of the coagulation cascade, leading to constitutive prolongation of routinely assessed coagulation studies. The level of laboratory abnormality that predicts bleeding is unclear, leading to varying transfusion therapy practices. METHODS: HIE infants treated with TH between 2008–2012 were included in this retrospective study. Initial, minimum (min) and maximum (max) values of International Normalized Ratio (INR), activated partial thromboplastin time (aPTT), fibrinogen (Fib) and platelet (PLT) count (measured twice daily during TH) were collected. Bleeding was defined as clinically significant if associated with 1) decreased hemoglobin (Hb) by 2 g/dL in 24 hours, 2) transfusion of blood products for hemostasis, or 3) involvement of a critical organ system. Laboratory data between the bleeding group (BG) and non-bleeding group (NBG) were compared. Variables that differed significantly between groups were evaluated with Receiver Operating Characteristic Curve (ROC) analyses to determine cut-points to predict bleeding. RESULTS: Laboratory and bleeding data were collected from a total of 76 HIE infants with a mean (±SD) birthweight of 3.34 ± 0.67 kg and gestational age of 38.6 ± 1.9 wks. BG included 41 infants. Bleeding sites were intracranial (n = 13), gastrointestinal (n = 19), pulmonary (n = 18), hematuria (n = 11) or other (n = 1). There were no differences between BG and NBG in baseline characteristics (p > 0.05). Both groups demonstrated INR and aPTT values beyond the acceptable reference ranges utilized for full tem newborns. BG had higher initial and max INR, initial aPTT, and lower min PLT and min Fib compared to NBG. ROC analyses revealed that platelet count <130 × 10(9)/L, fib level <1.5 g/L, and INR >2 discriminated BG from NBG. CONCLUSIONS: Laboratory evidence of coagulopathy is universal in HIE babies undergoing TH. Transfusion strategies to maintain PLT counts >130 × 10(9)/L, fib level >1.5 g/L, and INR <2 may prevent clinical bleeding in this high risk population.
format Online
Article
Text
id pubmed-4289197
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42891972015-01-11 Coagulopathy in newborns with hypoxic ischemic encephalopathy (HIE) treated with therapeutic hypothermia: a retrospective case-control study Forman, Katie R Diab, Yaser Wong, Edward CC Baumgart, Stephen Luban, Naomi LC Massaro, An N BMC Pediatr Research Article BACKGROUND: Newborns with hypoxic ischemic encephalopathy (HIE) are at risk for coagulopathy due to systemic oxygen deprivation. Additionally, therapeutic hypothermia (TH) slows enzymatic activity of the coagulation cascade, leading to constitutive prolongation of routinely assessed coagulation studies. The level of laboratory abnormality that predicts bleeding is unclear, leading to varying transfusion therapy practices. METHODS: HIE infants treated with TH between 2008–2012 were included in this retrospective study. Initial, minimum (min) and maximum (max) values of International Normalized Ratio (INR), activated partial thromboplastin time (aPTT), fibrinogen (Fib) and platelet (PLT) count (measured twice daily during TH) were collected. Bleeding was defined as clinically significant if associated with 1) decreased hemoglobin (Hb) by 2 g/dL in 24 hours, 2) transfusion of blood products for hemostasis, or 3) involvement of a critical organ system. Laboratory data between the bleeding group (BG) and non-bleeding group (NBG) were compared. Variables that differed significantly between groups were evaluated with Receiver Operating Characteristic Curve (ROC) analyses to determine cut-points to predict bleeding. RESULTS: Laboratory and bleeding data were collected from a total of 76 HIE infants with a mean (±SD) birthweight of 3.34 ± 0.67 kg and gestational age of 38.6 ± 1.9 wks. BG included 41 infants. Bleeding sites were intracranial (n = 13), gastrointestinal (n = 19), pulmonary (n = 18), hematuria (n = 11) or other (n = 1). There were no differences between BG and NBG in baseline characteristics (p > 0.05). Both groups demonstrated INR and aPTT values beyond the acceptable reference ranges utilized for full tem newborns. BG had higher initial and max INR, initial aPTT, and lower min PLT and min Fib compared to NBG. ROC analyses revealed that platelet count <130 × 10(9)/L, fib level <1.5 g/L, and INR >2 discriminated BG from NBG. CONCLUSIONS: Laboratory evidence of coagulopathy is universal in HIE babies undergoing TH. Transfusion strategies to maintain PLT counts >130 × 10(9)/L, fib level >1.5 g/L, and INR <2 may prevent clinical bleeding in this high risk population. BioMed Central 2014-11-03 /pmc/articles/PMC4289197/ /pubmed/25367591 http://dx.doi.org/10.1186/1471-2431-14-277 Text en © Forman et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Forman, Katie R
Diab, Yaser
Wong, Edward CC
Baumgart, Stephen
Luban, Naomi LC
Massaro, An N
Coagulopathy in newborns with hypoxic ischemic encephalopathy (HIE) treated with therapeutic hypothermia: a retrospective case-control study
title Coagulopathy in newborns with hypoxic ischemic encephalopathy (HIE) treated with therapeutic hypothermia: a retrospective case-control study
title_full Coagulopathy in newborns with hypoxic ischemic encephalopathy (HIE) treated with therapeutic hypothermia: a retrospective case-control study
title_fullStr Coagulopathy in newborns with hypoxic ischemic encephalopathy (HIE) treated with therapeutic hypothermia: a retrospective case-control study
title_full_unstemmed Coagulopathy in newborns with hypoxic ischemic encephalopathy (HIE) treated with therapeutic hypothermia: a retrospective case-control study
title_short Coagulopathy in newborns with hypoxic ischemic encephalopathy (HIE) treated with therapeutic hypothermia: a retrospective case-control study
title_sort coagulopathy in newborns with hypoxic ischemic encephalopathy (hie) treated with therapeutic hypothermia: a retrospective case-control study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289197/
https://www.ncbi.nlm.nih.gov/pubmed/25367591
http://dx.doi.org/10.1186/1471-2431-14-277
work_keys_str_mv AT formankatier coagulopathyinnewbornswithhypoxicischemicencephalopathyhietreatedwiththerapeutichypothermiaaretrospectivecasecontrolstudy
AT diabyaser coagulopathyinnewbornswithhypoxicischemicencephalopathyhietreatedwiththerapeutichypothermiaaretrospectivecasecontrolstudy
AT wongedwardcc coagulopathyinnewbornswithhypoxicischemicencephalopathyhietreatedwiththerapeutichypothermiaaretrospectivecasecontrolstudy
AT baumgartstephen coagulopathyinnewbornswithhypoxicischemicencephalopathyhietreatedwiththerapeutichypothermiaaretrospectivecasecontrolstudy
AT lubannaomilc coagulopathyinnewbornswithhypoxicischemicencephalopathyhietreatedwiththerapeutichypothermiaaretrospectivecasecontrolstudy
AT massaroann coagulopathyinnewbornswithhypoxicischemicencephalopathyhietreatedwiththerapeutichypothermiaaretrospectivecasecontrolstudy